trelstar and dienogest

The recurrence of deep infiltrating endometriosis (DIE) after its surgical excision is a big problem: postoperative treatment is crucial.. To compare two postoperative treatments: Dienogest and GnRH agonists.. Prospective Randomized Controlled Trial (RCT).. 146 women submitted to laparoscopic eradication of DIE with bowel and parametrial surgery.. The primary outcome was to demonstrate the non-inferiority of Dienogest about the reduction in pain recurrence. Secondary outcomes were differences in terms of treatment tolerability, side effects, imaging relapse rate, and pregnancy rate.. Both Dienogest and GnRH agonists were associated with a highly significant reduction of pain at 6 and 30 months, without any significant difference (. Dienogest has proven to be as effective as GnRH agonists in preventing recurrence of DIE and associated pelvic pain after surgery. Also, it is better tolerated by patients.

Topics: Endometriosis; Female; Gonadotropin-Releasing Hormone; Humans; Intestines; Laparoscopy; Leuprolide; Nandrolone; Pelvic Pain; Peritoneum; Postoperative Care; Pregnancy; Recurrence; Reoperation; Secondary Prevention; Treatment Outcome; Triptorelin Pamoate

To compare the efficacy of Dienogest versus Decapeptyl at 3.75 mg as consolidation therapy for surgery in the treatment of endometriosis.. Multicenter, open, randomized, parallel-group clinical trial.. Volunteer patients in an academic research environment.. Women with grade 2, 3, and 4 (

Topics: Adolescent; Adult; Alkaline Phosphatase; Cholesterol; Cholesterol, HDL; Combined Modality Therapy; Endometriosis; Female; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Laparoscopy; Nandrolone; Triptorelin Pamoate

To compare the efficacy of the oral dienogest versus triptorelin acetate injection for treatment of premenopausal menorrhagia and pelvic pains in women with uterine adenomyosis.. A total of 41 patients with adenomyosis suffering from pelvic pains and menorrhagia were recruited. First group was managed with oral dienogest (2 mg/day, orally) while the second group received triptorelin acetate (3.75 mg/4 weeks, subcutaneous injection) for 16 weeks. Outpatient follow-up was undertaken after 8 weeks but mean values were calculated at baseline and after 16 weeks (end of treatment).. A total of 41 women were allocated to treatment with dienogest (n = 22) or triptorelin acetate (n = 19); 19 (86.4 %) and 18 (94.7 %) % of the respective groups completed the trial. Significant reductions in pelvic pains after 16 weeks treatment were obtained in both groups demonstrating the equivalence of dienogest relative to triptorelin acetate. Triptorelin acetate was more effective in controlling of menorrhagia and reduction of uterine volume.. Dienogest may be a valuable alternative to depot triptorelin acetate for treatment of premenopausal pelvic pains in women with uterine adenomyosis.

Topics: Adenomyosis; Administration, Oral; Adult; Endometriosis; Female; Humans; Injections, Subcutaneous; Menorrhagia; Middle Aged; Nandrolone; Pelvic Pain; Premenopause; Prospective Studies; Treatment Outcome; Triptorelin Pamoate